IMMP News and Press, Immutep Limited From 05/04/22

Gainers: Bright Health Group BHG +21%. TransMedics Group TMDX +21%. Belite Bio (BLTE) +11%. Sharps Technology STSS +11%. Immutep (IMMP) +7%. Losers: Connect Biopharma CNTB -45%. Amarin AMRN -43%. Kezar Life Sciences (KZR) -35%. MacroGenic...

What You Need to Know About Buying Penny Stocks Today With another day of trading penny stocks and blue chips here, there is a lot that investors need to keep track of. In the past week or two, we’ve seen mostly bearish trading patterns. This is the result of overwhelming volatil...

Statistically significant increase in innate and adaptive immune response biomarkers (monocyte and CD8 T cell counts and serum CXCL10 levels) and absolute lymphocyte count (ALC) demonstrated in the efti group, but not in the placebo group The increase in pharmacodynamic markers is sig...

SYDNEY, AUSTRALIA, April 28, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3-related immunotherapy treatments for cancer and autoimmune disease, announces new interim ...

Shares of Immutep Limited (NASDAQ:IMMP) traded at a new 52-week high today of $7.95. So far today approximately 97.5 million shares have been exchanged, as compared to an average 30-day volume of 184,000 shares. Over the past year, Immutep Limited has traded in a range of $0.53 to $5.44 ...

All enrolled patients were 2 nd line metastatic non-small cell lung carcinoma (NSCLC) patients that had confirmed progressive disease after prior PD-1 or PD-L1 therapy (PD-X refractory) Encouraging interim Disease Control Rate (DCR) of 36.1% (13/36) and 26% progression free at 6 m...

Immutep (IMMP -8.8%) reported new interim data from Part B of its phase 2 trial of eftilagimod alpha (efti) in combination with Merck's Keytruda (pembrolizumab) as 2nd line therapy for patients with non-small cell lung cancer (NSCLC). The mid-stage study, called TACTI-002, is evalua...

New interim data from TACTI-002 (Part B) evaluating the combination of efti and pembrolizumab in 2nd line, confirmed PD-1/PD-L1 refractory, non-small cell lung cancer (NSCLC) patients Combination continues to be safe and well tolerated, and shows encouraging signs of antitumour activi...

FDA approval of Bristol Myers Opdualag/relatlimab anti-LAG3 carries positive implications for LAG3 pure-play Immutep’s entire pipeline. From an anti-LAG3 perspective, the FDA approval is directly positive for Immutep's recently unveiled oral, small molecule anti-LAG3 program an...

Clinical-stage biotech, Immutep Limited (NASDAQ:IMMP) announced on Friday that the Japanese Patent Office issued a second patent related to its experimental cancer therapy LAG525 co-developed by Swiss pharma giant Novartis (NYSE:NVS), The patent no. 7030750 titled “antibody molecules t...